U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07344922) titled 'SGLT2 Inhibitors in Non-Diabetic CKD: Effects on Vascular Calcification and Anemia' on Dec. 14, 2025.
Brief Summary: The goal of this clinical trial is to learn if the drug dapagliflozin (an SGLT2 inhibitor) can help protect the kidneys, improve anemia, and support heart health in adults with chronic kidney disease (CKD) who do not have diabetes. The main questions it aims to answer are:
Does dapagliflozin slow the worsening of kidney function compared to standard care?
Does dapagliflozin improve anemia by increasing hemoglobin and related blood markers?
Does dapagliflozin improve heart function and reduce cardiovascular problems...